Agenda

The NLA invites speakers and guests to provide scientific medical opinion, which do not necessarily reflect the policy of the NLA. The schedule and faculty are subject to change.

Faculty

Joyce L. Ross, MSN, ANP, CLS, CRNP, FPCNA, FNLA

Program Chair
President, National Lipid Association
Consultative Education Specialist,
  Cardiovascular Risk Intervention
University of Pennsylvania Health System- Retired
Philadelphia, PA

James A. Underberg, MD, MS, FNLA

Program Chair
President- Elect, National Lipid Association
Clinical Assistant Professor of Medicine
NYU School of Medicine & NYU Center for
Prevention of Cardiovascular Disease
Director, Bellevue Hospital Lipid Clinic
New York, NY
Diplomate, American Board of Clinical Lipidology

Christie M. Ballantyne, MD, FNLA

Planning Committee
Professor of Medicine
Chief, Section of Cardiovascular Research
Director, Center for Cardiovascular Disease Prevention
Baylor College of Medicine
Houston, TX
Diplomate, American Board of Clinical Lipidology

Dave L. Dixon, PharmD, BCPS, CDE, AACC, FNLA

Associate Professor, Ambulatory Care
Vice-Chair of Clinical Services
Department of Pharmacotherapy and Outcomes Science
Virginia Commonwealth University
School of Pharmacy
Richmond, VA

Daniel A. Duprez, MD, PhD, FAHA, FACC, FESC, FASH, FNLA

Planning Committee
Donald and Patricia Garofalo Chair in Preventive Cardiology
Professor of Medicine/Cardiology
Director Lipid Clinic
Director of Research of the Rasmussen Center for Cardiovascular Disease Prevention
Adjunct Professor Epidemiology and Community Health (School of Public Health)
Cardiovascular Division
University of Minnesota
Minneapolis, MN

Anne C. Goldberg, MD, FACP, FNLA

Planning Committee
President, Foundation of the NLA
Professor of Medicine
Washington University School of Medicine
St. Louis, MO
Diplomate, American Board of Clinical Lipidology

Robert Greenfield, MD, FACC, FAHA, FNLA

Planning Committee
University of California, Irvine
Memorial Health Care Hospitals
Orange Coast Memorial Hoag Hospital
Newport Beach Hoag Hospital
Irvine Fountain Valley Regional Medical Center
Fountain Valley, CA
Diplomate, American Board of Clinical Lipidology

Elizabeth Jackson MSN, ACNS-BC, CLS, FNLA

Planning Committee
Cardio Texas
St. David's Medical Center
Austin, TX

Wahida Karmally, DrPH, RD, CDE, CLS, FNLA

Planning Committee
Associate Research Scientist
Dean’s Faculty, College of Dental Medicine
Director of Nutrition
Irving Institute for Clinical and Translational Research
Columbia University
 New York, NY

Gay J. Meyers, PA-C, CLS

Planning Committee
Adjunct Faculty
University of Utah School of Medicine
Canyons Health and Wellness Center
Sandy, UT

Alan S. Brown, MD, FACC, FAHA, FNLA

Director, Division of Cardiology
Advocate Lutheran General Hospital
Medical Director, Midwest Heart Disease Prevention Center
Midwest Heart Specialists at Advocate Healthcare
Clinical Associate Professor of Medicine
Loyola University Stritch School of Medicine
Park Ridge, IL
Diplomate, American Board of Clinical Lipidology

Catherine Christie, PhD, RDN, LDN, FAND

Associate Dean, Graduate Nutrition Program Director
Department of Nutrition & Dietetics
Brooks College of Health
University of North Florida
Jacksonville, FL

Rhonda Cooper-Dehoff, PharmD

Associate Professor
College of Pharmacy
Associate Director
Center for Pharmacogenomics
University of Florida
Gainesville, FL

Robert H. Eckel, MD, FNLA

Charles A. Boettcher Endowed Chair in Atherosclerosis
Professor of Medicine - Division of Endocrinology Metabolism and Diabetes, and Cardiology
Professor of Physiology and Biophysics
Program Director, Adult General Clinical Research Center
University of Colorado
Anschutz Medical Campus
Aurora, CO
Diplomate, American Board of Clinical Lipidology

Edward Fisher, MD, PhD, FNLA

Director, The Lipid Treatment and Research Center
Professor of Cardiovascular Medicine
New York University
School of Medicine
New York, NY

Eugenia Gianos, MD, FNLA

Assistant Professor
Department of Medicine
NYULMC Center for the Prevention of Cardiovascular Disease
New York, NY
Diplomate, American Board of Clinical Lipidology

Ira J. Goldberg, MD, FNLA

Clarissa and Edgar Bronfman, Jr. Professor
Director, Division of Endocrinology, Diabetes and Metabolism
NYU Langone Medical Center
New York, NY

Robert A. Kloner, MD, PhD

Vice President of Translation
Huntington Medical Research Institutes
Keck School of Medicine at USC
Los Angeles, CA

Michael J. Koren, MD

CEO and Director
Jacksonville Center for Clinical Research
Encore Research Group
Jacksonville, FL

Michael Miller, MD, FACC, FAHA

Professor of Cardiovascular Medicine
Epidemiology & Public Health
University of Maryland School of Medicine
Director, Center for Preventive Cardiology
University of Maryland Medical Center
Baltimore, MD
Diplomate, American Board of Clinical Lipidology

Michael Ozner, MD, FACC, FAHA

Medical Director
Wellness & Prevention
Baptist Health South Florida
Miami, FL

Cynthia G. Rodriguez, DNP, ARNP, FNP-BC, CLS, FNLA

ARNP Cardiology
Watson Clinic
Lakeland, FL

Neil J. Stone, MD, FNLA

Medical Director, Center for Vascular Disease
Bluhm Cardiovascular Institute
Bonow Professor of Medicine
Northwestern University's Feinberg School of Medicine
Chicago, IL
Diplomate, American Board of Clinical Lipidology

Amy C. Sturm, MS, LGC

Associate Professor, Internal Medicine
Wexner Medical Center at The Ohio State University
Division of Human Genetics
Columbus, OH

Lindsey Sutton

Degreed Nutritionist
Bakersfield, CA

Allen J. Taylor MD, FACC FAHA

Chief, Cardiology Division
Medstar Georgetown University Hospital
Medstar Washington Hospital Center
Medstar Heart and Vascular Institute
Professor of Medicine, Georgetown University
Washington, DC

Beth A. Taylor, PhD

Associate Professor
Kinesiology
University of Connecticut
Director of Exercise Physiology Research, Cardiology
Hartford Hospital
Hartford, CT

Jonathan Tobert, MD

Academic Visitor
Nuffield Department of Population Health
University of Oxford
Oxford, UK

Kevin Jon Williams, MD

Section Chief, Endocrinology, Diabetes and Metabolism
Professor, Medicine
Professor, Physiology
Professor, Cardiovascular Research Center
Lewis Katz School of Medicine
Temple University
Philadelphia, PA

Peter W.F. Wilson, MD, FNLA

Professor of Medicine
Division of Cardiology
Emory University School of Medicine
Professor of Public Health
Rollins School of Public Health
Director, Epidemiology and Genomic Medicine
Atlanta VA Medical Center
Atlanta, GA
Diplomate, American Board of Clinical Lipidology

 

Featured Sessions

Accreditation

Target Audience
This activity is designed to meet the needs of physicians, physician assistants, pharmacists, registered nurses, nurse practitioners, advance practice registered nurses and registered dietitians with an interest in lipid management.

Educational Objectives
At the conclusion of this activity, registered nurses and nurse practitioners should be able to provide appropriate counsel for patients and their families.

At the conclusion of this activity, all participants should be able to:

Session I- Practical Insights into Clinical Prevention and Dyslipidemia Management

• Review management strategies for the primary prevention of ASCVD
• Discuss how novel and emerging therapies can best be integrated into clinical practice
• Describe the pathophysiology of type 2 diabetes and metabolic syndrome, including the characteristic atherogenic dyslipidemia found in these patients

Keynote Saturday-

• Review the impact on cardiovascular risk of atherosclerotic plaque development and progression

Session II- Technology and Fatty Acids: Meeting the Players in CVD Prevention

• Review the use of non-invasive coronary and carotid imaging and its role for cardiovascular disease risk assessment
• Identify the impact of omega-3 fatty acids on lipids, lipoproteins and ASCVD risk reduction

Session III- Understanding the Role of Nutrition in CV Health

• Discuss the evidence that supports the benefits of personalized nutritional counseling and its impact on ASCVD, dyslipidemia, diabetes, metabolic syndrome, and obesity
• Describe the role of insulin in metabolic syndrome, obesity, and ASCVD risk

Session IV: Debating the Nocebo Effect

• Discuss current literature regarding statin medications and muscle related side effects

Session V- The Future of Lipid-Lowering Therapies- Are We Ready?

• Assess current and evolving perspectives on lipid altering medications
• Identify statin-influenced pathways that may contribute to variability in clinical efficacy, as well as to risk of adverse events
• Assess the safety and efficacy of lipid altering and non-lipid effects of PCSK9 inhibitors

Session VI-  What You Need to Know About Triglyceride Management

• Discuss the genetic basis and mechanistic of inherited triglyceride disorders
• Discuss evidence regarding triglycerides as a risk factor for cardiovascular disease including the clinical implications for patient management
• Assess the status of current and emerging treatment options for lowering triglycerides

Keynote Sunday-

• Discuss the role of statin therapy in the management of patients with type 1 diabetes

Session VII- Discussing Unknown Risk Factors with your Patient

• Explain the role of the genetic counselor in the care of patients with inherited lipid disorders
• Identify the epidemiology and pathophysiologic links between erectile dysfunction and ASCVD risk
• Explain the role of testosterone therapy in the patient with or at risk for ASCVD

CME credit provided by the National Lipid Association

Physicians
The National Lipid Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The National Lipid Association designates this live activity for a maximum of 12 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in this activity.

Physician Assistants
NCCPA accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.

Dietitians
The National Lipid Association is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). Registered dietitians (RDs) and dietetic technicians, registered (DTRs) will receive 12 continuing professional education units (CPEUs) for completion of this program/ materials. CDR Accredited Provider #NL002.

CE credit provided by Postgraduate Institute for Medicine

Pharmacists
Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Session I- Universal Activity Number 0809-9999-16-335-L01-P (Knowledge)
Postgraduate Institute for Medicine designates this continuing education activity for 2.00 contact hour(s) (.20 CEUs) of the Accreditation Council for Pharmacy Education

Keynote- Session I- Universal Activity Number 0809-9999-16-334-L01-P (Knowledge)
Postgraduate Institute for Medicine designates this continuing education activity for .75 contact hour(s) (.075 CEUs) of the Accreditation Council for Pharmacy Education

Session II- Universal Activity Number 0809-9999-16-336-L01-P (Knowledge)
Postgraduate Institute for Medicine designates this continuing education activity for 1.25 contact hour(s) (.125 CEUs) of the Accreditation Council for Pharmacy Education

Session III – Universal Activity Number 0809-9999-16-337-L01-P (Knowledge)
Postgraduate Institute for Medicine designates this continuing education activity for .75 contact hour(s) (.75 CEUs) of the Accreditation Council for Pharmacy Education

Session IV– Universal Activity Number 0809-9999-16-338-L01-P (Knowledge)
Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour(s) (.10 CEUs) of the Accreditation Council for Pharmacy Education

Session V – Universal Activity Number 0809-9999-16-339-L01-P (Knowledge)
Postgraduate Institute for Medicine designates this continuing education activity for 1.75 contact hour(s) (.175 CEUs) of the Accreditation Council for Pharmacy Education

Session VI – Universal Activity Number 0809-9999-16-340-L01-P (Knowledge)
Postgraduate Institute for Medicine designates this continuing education activity for 1.75 contact hour(s) (.175 CEUs) of the Accreditation Council for Pharmacy Education

Keynote- Session II- Universal Activity Number 0809-9999-16-362-L01-P (Knowledge)
Postgraduate Institute for Medicine designates this continuing education activity for .75 contact hour(s) (.075 CEUs) of the Accreditation Council for Pharmacy Education

Session VII – Universal Activity Number 0809-9999-16-363-L01-P (Knowledge)
Postgraduate Institute for Medicine designates this continuing education activity for 1.25 contact hour(s) (.125 CEUs) of the Accreditation Council for Pharmacy Education

Nursing
This educational activity for 10.6 contact hours is provided by the Postgraduate Institute for Medicine.
Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
Session I- 2.0 credits; Keynote I- 0.7; Session II- 1.10 credits; Session III- .80 credits; Session IV- 0.9 credits; Session V- 1.6 credits; Session VI- 1.6 credits, Keynote II- 0.6 credits, Session VII- 1.3 credits.

Pharmacotherapy contact hours for Advance Practice Registered Nurses to be determined.

Criteria for Success:
Statements of credit will be awarded based on the participant´s attendance and submission of the activity evaluation form. A statement of credit will be available upon completion of an online evaluation/claimed credit form at www.lipid.org/cme.
For Pharmacists: Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

Disclosure Statement:
It is the policy of NLA to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by NLA prior to accreditation of the activity. NLA planners and reviewers have no relevant financial relationships to disclose.

Commercial Support:
Full notification of commercial support will be provided in the activity syllabus.

Pre-Conference Courses

The NLA’s Masters in Lipidology Course is an intensive 2-day training course offers an in-depth review of the core curriculum in Clinical Lipidology for health care professionals who desire to practice at an advanced level within the field. Learn from leading experts, assess your knowledge of lipid science and advance your personal standard of practice.
 

The NLA's Lipid Academy provides a comprehensive, in-depth indoctrination to lipid science and is open to all health care professionals interested in developing a core competency in the diagnosis and treatment of dyslipidemia. The interactive Lipid Academy course provides health professionals with the knowledge and tools necessary to work effectively in a lipid practice, and will serve as a preparatory course for the Annual Scientific Forum and other advanced lipid training.
 

Abstracts

Abstracts Coming Soon

This information is still being developed by our program developers. Please check back soon for updates to be posted as soon as they are available. Also, check for updates in your email. If you are not currently on our emal blast list and you would like to receive communications from and information about NLA programs, Click Here to sign up.

Foundation Event

Mini Golf Adventure with the Foundation

Saturday, August 27, 2016
6:30–8:30 PM

$40/person

Join the Foundation of the National Lipid Association for a fun-filled evening of mini golf! Engage your peers in a friendly competition through 18 holes on the Heron Cove Adventure Golf course. The winning team will take home prizes and bragging rights. Enjoy a cash-bar, ping pong, and oversized board games on the course. A portion of your ticket will be donated to the Foundation.

Meet in the hotel lobby for a brief 3-5 minute walk to the mini golf course

CME Symposia

The Provider's Approach to PCSK9 Antibodies

Friday, August 26th
6:45 – 9:00 pm
Omni Amelia Island - Magnolia Ballroom D

Learn more about this CME/CE Symposium.

Expert Theaters

Saturday, August 27th

Is It Time to Change Our CVD Risk Assessment Paradigm?
Speaker: Peter Alagona, MD

7:00-7:50 AM
Cumberland Ballroom BC
Sponsored by Quest Diagnostics

PRALUENT® (alirocumab) Injection: Clinical Advancement for LDL-C Management
Speaker: Michael Koren, MD, FACC, CPI

7:00-7:50 AM
Cumberland Ballroom A
Sponsored by Sanofi Regeneron

Repatha® (evolocumab): A Clinical Overview
Speaker: Michael Bloch, MD

3:00-3:55 PM
Cumberland Ballroom BC
Sponsored by Amgen Inc.

Honors and Awards Ceremony

Honors and Awards Ceremony Coming Soon

This information is still being developed by our program developers. Please check back soon for updates to be posted as soon as they are available. Also, check for updates in your email. If you are not currently on our emal blast list and you would like to receive communications from and information about NLA programs, Click Here to sign up.

Mentor and Mentee Reception

Mentors and Mentees Coming Soon

This information is still being developed by our program developers. Please check back soon for updates to be posted as soon as they are available. Also, check for updates in your email. If you are not currently on our emal blast list and you would like to receive communications from and information about NLA programs, Click Here to sign up.

Mobile App

The National Lipid Association will be providing an app with onsite updates and educational content for attendees. The app will be available on mobile devices, tablets, and laptops. Information regarding downloading the app will be sent to registered attendees prior to the meeting.

Social Media

Coming Soon

This information is still being developed by our program developers. Please check back soon for updates to be posted as soon as they are available. Also, check for updates in your email. If you are not currently on our emal blast list and you would like to receive communications from and information about NLA programs, Click Here to sign up.

Support Recognition

Accreditation Council for Clinical Lipidology (ACCL)
The ACCL establishes, certifies, and maintains the clinical competencies of qualified and experienced healthcare professionals specializing in Clinical Lipidology (non-physician and physician). Two levels of certification offered: Clinical Lipid Specialist (CLS) and Lipid Competency Certificate (LCC).
www.lipidspecialist.org

Aegerion Pharmaceuticals
www.Aegerion.com

Akcea Therapeutics
Akcea Therapeutics, a subsidiary of Ionis Pharmaceuticals, Inc., is focused on the development and commercialization of new treatments for patients with serious cardiometabolic lipid disorders.
www.akceatx.com

Alexion Pharmaceuticals
Alexion develops therapies for patients with devastating rare disorders and received recent FDA approval for two innovative enzyme replacement therapies – Strensiq® (asfotase alfa) to treat patients with hypophosphatasia (HPP) and Kanuma™ (sebelipase alfa) to treat patients with lysosomal acid lipase deficiency (LAL-D). Visit us to learn more about LAL-D – a life-threatening liver disease
www.alexion.com

Amarin Corporation
Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Vascepa® (icosapent ethyl), Amarin's first FDA approved product, is a highly-pure, EPA-only, omega-3 fatty acid product available by prescription. For more information about Vascepa visit www.vascepa.com. For more information visit www.amarincorp.com

Ambry Genetics
www.ambrygen.com

American Board of Clinical Lipidology (ABCL)
The ABCL assesses and validates the specialized knowledge and advanced training required to practice in the dynamic and complex field of Lipidology. The only certification program of its kind available to licensed physicians in the United States or Canada.
www.lipidboard.org

Amgen
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. A biotechnology pioneer since 1980, Amgen has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
www.amgen.com

Boston Heart Diagnostics
Boston Heart is transforming the treatment of cardiovascular disease by providing healthcare providers and their patients with novel, personalized diagnostics and reports with integrated, customized lifestyle programs.
www.bostonheartdiagnostics.com

CardioDx, Inc.
CardioDx, a molecular diagnostics company specializing in cardiovascular genomics, is committed to developing clinically validated tests that empower clinicians to better tailor care to each individual patient. www.cardiodx.com

Kaneka Pharma America
Kaneka’s Liposorber Apheresis System is FDA approved for the acute reduction of LDL cholesterol (70-80%) in patients with Familial Hypercholesterolemia and patients who cannot meet their LDL-C goals despite maximum drug therapy. The Liposorber treatment is reimbursed by government and private insurance, and is used in hospitals, clinics, and physician offices across the country.
www.liposorber.com

Kastle Therapeutics
Our Mission is to serve patients who have significant unmet medical needs and are underserved. To solve challenges for therapeutic developers and manufacturers. To support quality of care for patients with severe diseases. http://www.kastletherapeutics.com/

Kowa Pharmaceuticals America, Inc.
Kowa Pharmaceuticals America, Inc. delivers value-based solutions to patients by investing in the advancement of cardiometabolic therapeutics. The company's flagship product is LIVALO® (pitavastatin) tablets 1mg, 2mg, 4mg.
www.livalohcp.com

Mayo Medical Laboratories
Mayo Medical Laboratories provides advanced laboratory testing and pathology services to support 5,000 health care organizations around the world. Revenue from this testing is used to support medical education and research at Mayo Clinic, a nonprofit worldwide leader in medical care, research, and education for people from all walks of life. Complemented by collaborations with diagnostic and biotechnology companies, the department maintains a robust diagnostic test-development program, launching more than 150 new tests each year. http://www.mayomedicallaboratories.com/

MyGenetx
MyGenetx is a CLIA certified, molecular and general chemistry laboratory, providing timely and
comprehensive test results. We have a national footprint in the areas of Cardiology, Preventive
Medicine, Pharmacogenetics, Chronic Disease Management, Corporate Wellness, and Rural
Health. Our research and innovative ideas in genetic testing are at the forefront, allowing us to
offer personalized medicine and specialized healthcare options, beyond the traditional standard
of care. Our testing is affordable, accessible, and actionable. www.mygenetx.com

Quest Diagnostics
Quest Diagnostics, the world’s leading provider of diagnostic testing, information and services, offers the Cardio IQ Solution—a comprehensive approach to heart health. Visit 4myheart.com and QuestDiagnostics.com.

ReachMD
ReachMD is an award-winning medical broadcasting company delivering education and information to healthcare professionals nationwide through an on air, online, and mobile distribution network.
www.reachmd.com

Sanofi-Regeneron
Sanofi, a global healthcare leader, discovers, develops, and distributes therapeutic solutions focused on patients’ needs. Regeneron, a leading biopharmaceutical company, discovers, develops, manufactures, and commercializes biologic medicines for serious medical conditions. Since 2007, Sanofi and Regeneron have collaborated to develop and commercialize fully human monoclonal antibodies utilizing proprietary technologies.
www.regeneron.com

The Lipoprotein(a) Foundation
The Lipoprotein(a) Foundation is a patient-founded, nonprofit organization dedicated to advocacy, community education, patient support and research into the causes and health consequences of high Lipoprotein(a). Our mission is to reveal this inherited lipid/cholesterol risk for early cardiovascular disease; educate and empower patients, and save lives. We are advocating to include Lp(a) testing in the standard lipid/cholesterol blood testing panel increasing the rate of early diagnosis providing an accurate prediction of risk and promoting aggressive primary and secondary prevention. If left undiagnosed and treated, high Lp(a) can lead to early cardiovascular disease in women, men and children of all racial backgrounds.
www.lipoproteinafoundation.org/

UniQure, Inc
uniQure is a leader in gene therapy. Gene therapy offers the prospect of long-term benefit to patients with genetic or acquired diseases through a single therapeutic administration. uniQure is advancing its pipeline of novel adeno-associated virus (AAV)-based gene therapies with a focus on rare diseases including lipoprotein lipase deficiency. http://uniqure.com/

Virtual Exhibit Hall

Virtual Exhibit Hall Coming Soon

This information is still being developed by our program developers. Please check back soon for updates to be posted as soon as they are available. Also, check for updates in your email. If you are not currently on our emal blast list and you would like to receive communications from and information about NLA programs, Click Here to sign up.

Industry Council

Industry Council coming soon...

Media Partners

Omni Amelia Island Plantation Resort

Omni Amelia Island Plantation Resort
39 Beach Lagoon Rd
Amelia Island, FL 32034

Meeting Room Rate: $189/night++
Room Reservation Cut-Off Date: July 25, 2016
For reservations call 1-888-261-6161 and ask for the National Lipid Association room rate.

Omni Amelia Island Plantation Resort is nestled on 1,350 acres at the tip of a barrier island just off the Northeast Florida coast. Enjoy luxurious oceanfront accommodations, world-class resort pools, championship golf, full-service spa, endless dining options, and family-friendly activities.

Local Attractions

Attractions/Travel Information Coming Soon

This information is still being developed by our program developers. Please check back soon for updates to be posted as soon as they are available. Also, check for updates in your email. If you are not currently on our emal blast list and you would like to receive communications from and information about NLA programs, Click Here to sign up.

Late Breakers

Late Breaker Coming Soon

This information is still being developed by our program developers. Please check back soon for updates to be posted as soon as they are available. Also, check for updates in your email. If you are not currently on our emal blast list and you would like to receive communications from and information about NLA programs, Click Here to sign up.

Exhibit in Amelia Island

Several hundred health professionals will gather at the 2016 NLA Fall Clinical Lipid Update to benefit from comprehensive education sessions, to interact with their colleagues and to explore the exhibit hall.  Sponsorships and exhibits are designed to provide a solid platform to help you stand out and make an impact.  As an exhibitor, increase your presence at this meeting by taking advantage of exhibitor-only sponsorship opportunities and showcase what your company has to offer.

We look forward to you having you join us in Amelia Island.

Exhibit and sponsorship packages available. For more information or questions, please contact:
Leia Hutfles, Meeting Coordinator
(p) 904-309-6207 (e) exhibits@lipid.org

Online Registration for the Fall CLU is now closed. We will be taking registrations onsite.